SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

The clinical scenarios pertain to managing patients with established (or latent) CVD or an estimated moderate-to-high risk of CVD. These scenarios are essentially encompassed by Type 2 diabetes.

ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic ...

H.C. Wainwright lowered the firm’s price target on 89bio (ETNB) to $21 from $29 and keeps a Buy rating on the shares. The company announced ...

Shares of Altimmune Inc. (ALT) soared over 8% on Thursday, marking their best session in nearly three months, and extended ...

Familial chilomicronemia syndrome (FCS) is a genetic disease that causes persistent accumulation of triglycerides in the ...

American Association of Clinical Endocrinology (AACE) guidelines offer evidence-based recommendations for the pharmacologic ...

Ionis Pharmaceuticals Inc (NASDAQ:IONS) reported a fourth-quarter EPS loss of $0.66, up from a loss of $0.06, beating the ...

In a new survey, 97% of Americans said they believe supplements can improve heart health, but experts say there's little ...

You may be familiar with high-density, or good cholesterol; low-density lipoproteins (LDL), or bad cholesterol; and their ...

Bio Inc ( ($ETNB) ) has released its Q4 earnings. Here is a breakdown of the information 89Bio Inc presented to its investors. 89bio Inc., a ...